Methylation of NEUROG1 in Serum Is a Sensitive Marker for the Detection of Early Colorectal Cancer

Herbst, Andreas; Rahmig, Konstanze; Stieber, P.; Philipp, Alexander; Jung, Andreas; Ofner, Andrea; Crispin, Alexander; Neumann, Jens; Lamerz, R.; Kolligs, Frank T.

doi:10.1038/ajg.2011.6

Cited by 110 publications

(104 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bisulfite treatment and methylation specific polymerase chain reaction (PCR) are the two most commonly used techniques. A blood biomarker with a high sensitivity and specificity for CRC can not only be used to segregate high-risk patients for further clinical tests but also be an excellent tool for monitoring CRC recurrence in patients who have undergone tumor resection (Table 1) [20][21][22][23][24][25][26][27][28][29][30] .…”

Section: Biomarkers Of Dna Methylation In Bloodmentioning

confidence: 99%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) causes approximately 600000 deaths annually and is the third leading cause of cancer mortality worldwide. Despite significant advancements in treatment options, CRC patient survival is still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision making. Since there exists a need to find new biomarkers to improve diagnosis of CRC, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to clinical practice. Epigenetic alterations are thought to hold great promise as tumor biomarkers. In this review, we will primarily focus on recent advances in the study of epigenetic biomarkers for colorectal cancer and discuss epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, in cancer tissue, stool, plasma, serum, cell lines and xenografts. These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapy choice and recurrence surveillance for CRC patients. However, these studies have typically been small in size, and evaluation at a larger scale of well-controlled randomized clinical trials is the next step that is necessary to increase the quality of epigenetic biomarkers and ensure their widespread clinical use.

show abstract

Section: Biomarkers Of Dna Methylation In Bloodmentioning

confidence: 99%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

show abstract

“…51,73,74 Promising results have also been reported using multigene methylation signatures for CRC screening in order to increase sensitivity and specificity. [61][62][63][64][65][66][67][68][69] For example, an approach using a BCAT1 and IKZF1 methylation assay identified approximately 70% of CRC. [75][76][77] Detection of tumor recurrence, minimal residual disease, and prognosis value Surgery alone cures a large fraction of patients with localized CRC.…”

Section: Cancer Diagnosis and Screeningmentioning

confidence: 99%

“…60 DNA methylation is an early event in CRC carcinogenesis, and various studies have investigated the use of methylated ctDNA for CRC screening and diagnosis (Table 2). [61][62][63][64][65][66][67][68][69] Several studies evaluated the pretreatment methylation status of the Septin 9 (SEPT9) gene promoter. SEPT9 methylation demonstrated a sensitivity of about 70% (50%-90%) and a specificity of about 90% (70%-100%) to detect CRC, depending on disease stage (metastatic vs non-metastatic).…”

Section: Cancer Diagnosis and Screeningmentioning

confidence: 99%

Future perspectives of circulating tumor DNA in colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Tumor biopsy is currently the gold standard for diagnosis and in determining cell signaling pathways involved in the development of treatment resistance. However, there are major challenges with this technique, including the need for serial sampling to monitor treatment resistance, which is invasive and also has the potential for selection bias due to intra-tumoral and inter-tumoral heterogeneity. These challenges highlight the need for more effective methods for obtaining Tumor samples. Liquid biopsy analyzes genetic material or tumor cells shed into the blood from the primary tumor and metastatic sites and consequently provides a comprehensive, real-time picture of the tumor burden in an individual patient. Indeed, liquid biopsy has the potential to revolutionize cancer management. Here, we review recent studies on the potential clinical applications of liquid biopsy using circulating tumor DNA in colorectal cancer, including screening, diagnosis, detection of minimal residual disease after surgery, detection of recurrence, prognosis, predicting treatment response, monitoring tumor burden or response during treatment, and tracking resistance. We also discuss recent data demonstrating the utility of detecting KRAS-mutated circulating tumor DNA, both at diagnosis to determine an appropriate treatment strategy and during anti-epidermal growth factor receptor therapy to predict treatment resistance. The future integration of liquid biopsy into clinical practice is discussed, together with alternative approaches and key questions that need to be answered in future clinical studies before this technology can be implemented and used routinely.

show abstract

“…Besides its importance as a gene inactivation mechanism, promoter CpG island hypermethylation is gaining attention as a potential tumor biomarker. In this respect, DNA methylation markers are being actively investigated to detect human cancers in blood, secretions, or exfoliated cytology specimens and to predict the risk of cancer progression and development (Herbst et al, 2011). For biomarkers to be most useful for early detection or screening, one would need to be able to detect the markers without biopsy, such as in the circulation (Chang et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Disease Progression from Chronic Hepatitis C to Cirrhosis and Hepatocellular Carcinoma is Associated with Increasing DNA Promoter Methylation

Zekri

Nassar

Elrouby

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The epigenetic changes observed in this study indicate that HCC tumors exhibit specific DNA methylation signatures with potential clinical applications in diagnosis and prognosis. In addition, methylation frequency could be used to monitor whether a patient with chronic hepatitis C is likely to progress to liver cirrhosis or even HCC. We can conclude that methylation processes are not just early events in hepatocarcinogenesis but accumulate with progression to cancer.

show abstract

Methylation of NEUROG1 in Serum Is a Sensitive Marker for the Detection of Early Colorectal Cancer

Abstract: Methylation of the NEUROG1 gene is frequently found in sera of patients with colorectal cancers independent of tumor stage. The quantitative detection of NEUROG1 DNA methylation in serum is a suitable approach for the non-invasive screening for asymptomatic colorectal cancer.

Cited by 110 publications

References 34 publications

Advances in epigenetic biomarker research in colorectal cancer

Advances in epigenetic biomarker research in colorectal cancer

Future perspectives of circulating tumor DNA in colorectal cancer

Disease Progression from Chronic Hepatitis C to Cirrhosis and Hepatocellular Carcinoma is Associated with Increasing DNA Promoter Methylation

Contact Info

Product

Resources

About